NOVONIX Ltd Files Form 6-K with Appendix 2A
Ticker: NVNXF · Form: 6-K · Filed: Jul 12, 2024 · CIK: 1859795
Sentiment: neutral
Topics: sec-filing, 6-K, disclosure
TL;DR
NOVONIX filed a 6-K on 7/12/24 with an Appendix 2A, check it for updates.
AI Summary
NOVONIX Limited filed a Form 6-K on July 12, 2024, reporting information as of July 12, 2024. The filing includes Exhibit 99.1, which is Appendix 2A. The company is incorporated in Australia and its fiscal year ends on December 31.
Why It Matters
This filing provides an update on company activities and disclosures, which is important for investors to stay informed about the latest developments at NOVONIX Limited.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- NOVONIX Limited (company) — Registrant
- July 12, 2024 (date) — Filing Date
- Appendix 2A (document) — Included Exhibit
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the registrant makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is included in this specific Form 6-K filing?
This Form 6-K includes Exhibit 99.1, which is described as Appendix 2A.
When was this Form 6-K filed?
This Form 6-K was filed on July 12, 2024.
Where is NOVONIX Limited based?
NOVONIX Limited is based in Brisbane, Australia.
Does NOVONIX Limited file annual reports on Form 20-F or 40-F?
NOVONIX Limited indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-07-12 16:59:32
Filing Documents
- nvx-6k-july-24-07-12-app.htm (6-K) — 18KB
- nvx-ex99_1.htm (EX-99.1) — 82KB
- img58969013_0.jpg (GRAPHIC) — 1KB
- 0000950170-24-083260.txt ( ) — 103KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: July 12, 2024